Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We investigated the characteristics and utility of gadobenate dimeglumine (Gd-BOPTA) for MRI of the mouse liver. Mice were imaged under isoflurane anesthesia using a T(1)-weighted, three-dimensional fast low-angle shot (3D FLASH) sequence before and after intravenous or subcutaneous injection of Gd-BOPTA, and the time course of the contrast effect was examined. The appropriate dose for subcutaneous injection was determined visually, and the inter- and intra-observer reproducibilities in liver volumetry were evaluated with and without contrast injection. When mice were imaged sequentially before and after Gd-BOPTA injection and isoflurane anesthesia was maintained throughout the experiment, a long-lasting contrast effect was noted in the liver. Subcutaneous injection caused delayed, but favorable, enhancement. Washout from the liver was definitely accelerated in conscious mice in comparison with anesthetized mice. Visual evaluation indicated that a dose of 0.1 mmol/kg was appropriate for clear delineation of the entire liver margin, and the application of Gd-BOPTA significantly improved the inter- and intra-observer reproducibilities of liver volumetry. In conclusion, the intravenous or subcutaneous injection of Gd-BOPTA has a favorable contrast effect for the mouse liver, resulting in clear visualization of the liver border and improved reproducibility of liver volumetry. The possible influence of anesthesia on the pharmacokinetics of a contrast agent should be considered in determining the optimal scan timing.

Download full-text PDF

Source
http://dx.doi.org/10.1002/nbm.1135DOI Listing

Publication Analysis

Top Keywords

subcutaneous injection
16
mouse liver
12
liver volumetry
12
liver
10
gadobenate dimeglumine
8
contrast agent
8
mri mouse
8
mice imaged
8
isoflurane anesthesia
8
intravenous subcutaneous
8

Similar Publications

Objective: To compare horses' aversive behavioural responses to the application of 5% prilocaine/lidocaine eutectic mixture of local anaesthetics (EMLA) cream versus subcutaneous infiltration of 2% lidocaine, followed by jugular vein catheterization.

Study Design: Blinded, randomized study.

Animals: A group of 26 university-owned research horses.

View Article and Find Full Text PDF

This study explores effective treatment methods for chronic secondary lymphedema after radical cervical cancer surgery combined with pelvic lymphadenectomy. In cases where conservative treatment was ineffective, we investigated whether multiple injections of indocyanine green can effectively improve the outcomes of lymphatic-venous anastomosis under microscopy. Preoperative lymphatic imaging was used to localize functional vessels, guiding distal left lower limb lymphatic reconstruction.

View Article and Find Full Text PDF

IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.

View Article and Find Full Text PDF

Background And Aims: Liver metastasis significantly contributes to poor survival in patients with colorectal cancer (CRC), posing therapeutic challenges due to limited understanding of its mechanisms. We aimed to identify a potential target critical for CRC liver metastasis.

Methods: We analyzed the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases and identified EphrinA3 (EFNA3) as a potential clinically relevant target.

View Article and Find Full Text PDF

Background: While pegylated Escherichia coli asparaginase (PEG) is an integral component of leukemia and lymphoma treatment, hypersensitivity reactions (HSR) remain a common adverse event, often resulting in adjustments to the treatment regimen, increasing the burden on patients and families. HSR to asparaginase often indicates a transition to Erwinia asparaginase (ERW), which requires patients to return to the hospital 6 times for subcutaneous injections to replace one dose of IV PEG. Previous trials have demonstrated rates of HSR to pegylated E.

View Article and Find Full Text PDF